IMIC(SZ:000516) Sou Hu Cai Jing·2026-01-28 12:54Core Viewpoint - International Medical (000516) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance and market position [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [2]. - The net profit after deducting non-recurring items was -312 million yuan, a decline of 41.94% [2]. - In Q3 2025, the single-quarter main revenue was 961 million yuan, a year-on-year decrease of 18.95% [2]. - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -123 million yuan, down 52.03% year-on-year [2]. - The company's debt ratio stood at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan [2]. - The gross profit margin was 6.59% [2]. Market Activity - As of January 28, 2026, the stock closed at 4.99 yuan, down 1.58%, with a turnover rate of 2.17% and a trading volume of 478,100 hands, amounting to a transaction value of 239 million yuan [1]. - On January 28, 2026, the net outflow of main funds was 38.6474 million yuan, accounting for 16.15% of the total transaction value [1]. - The net outflow of speculative funds was 1.4937 million yuan, representing 0.62% of the total transaction value [1]. - Retail investors had a net inflow of 40.1411 million yuan, making up 16.78% of the total transaction value [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions over the past 90 days is 5.5 yuan [3].